Key result
Long-term LMWH (tinzaparin) was associated with a reduced risk of postthrombotic syndrome compared to usual care in patients with proximal DVT.
Why the study?
Does long-term tinzaparin reduce the development of postthrombotic syndrome compared to usual care in patients with proximal DVT?
Cohort (n=480)
Does long-term tinzaparin reduce the development of postthrombotic syndrome compared to usual care in patients with proximal DVT?
Long-term LMWH (tinzaparin) may be an effective alternative to standard warfarin therapy for preventing postthrombotic syndrome in patients with proximal DVT.
Answers are grounded in this paper and cite their sources.
Should not yet change PTS prevention practice in proximal DVT; supports randomized trials of long-term tinzaparin.
Patients with iliac deep vein thrombosis (DVT) have a poor prognosis and high incidence of postthrombotic syndrome (PTS). We evaluated the effect of low-molecular-weight heparin (LMWH; tinzaparin) versus usual care (tinzaparin plus warfarin for ≥12 weeks at home) in the development of PTS according to DVT location (iliac/noniliac) by retrospective analysis of the Home-LITE cohort (480 patients with proximal DVT). Patients with iliac DVT had an overall odds ratio of 0.53 (95% confidence interval [CI] 0.33, 0.83; P = .0079) for PTS (including ulcer data) in favor of tinzaparin. Patients with noniliac DVT had a similar odds ratio (0.79 [95% CI 0.67, 0.93], P = .0046) to that reported in the overall Home-LITE population (0.76 [95% CI 0.66, 0.89], P = .0004; including ulcer data), both in favor of tinzaparin. Long-term LMWH may be a suitable alternative for the prevention of PTS in patients with iliac DVT who are unlikely to undergo invasive thrombolysis.
No takes yet. Share an insight, caveat, or question.
Hull et al. (2013) conducted a cohort in Proximal deep vein thrombosis (iliac/noniliac) (n=480). Low-molecular-weight heparin (tinzaparin) vs. Usual care (tinzaparin plus warfarin for ≥12 weeks at home) was evaluated on Postthrombotic syndrome (PTS) (OR 0.76, 95% CI 0.66-0.89, p=0.0004). Long-term LMWH (tinzaparin) was associated with a reduced risk of postthrombotic syndrome compared to usual care in patients with proximal DVT.
Synapse has enriched 10 related papers. Consider them for comparative context: